Distinguished in Meckel's Diverticulum

Ciro D. Esposito

Naples, IT 
Distinguished in Meckel's Diverticulum
Naples, IT 
OverviewLocationsClinical Research

Overview

Ciro Esposito practices in Naples, Italy. Mr. Esposito is rated as a Distinguished expert by MediFind in the treatment of Meckel's Diverticulum. His top areas of expertise are Congenital Giant Megaureter, Hydrocele, UPJ Obstruction, Endoscopy, and Nephrectomy.

His clinical research consists of co-authoring 343 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Meckel's Diverticulum.

Gender
Male

Locations

Naples, Italy
Other Locations
Pavia, 27100, Italy
Foggia, 71122, Italy
Via Marconi 1, Codogno, 26900, Italy
Lodi, Italy
Rome, 00146, Italy
Ravenna, Italy
Padova, Italy
Naples, Via Pansini 5 80131 Naples Italy, Via, 80131, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 2
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2025
Intervention Type: Drug
Study Drugs: Sparsentan, Irbesartan
Study Phase: Phase 3
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
Enrollment Status: Terminated
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drug: Bardoxolone
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 3
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Drugs: Daprodustat, Darbepoetin Alpha
Study Phase: Phase 3
A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo
A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Phase: Phase 3
Non-Interventional, Exploratory, Phase IV, Single-Blind, Cross-Sectional, Randomised, Cross-over Study Evaluating Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease & Hyperkalaemia (APPETIZE).
Non-Interventional, Exploratory, Phase IV, Single-Blind, Cross-Sectional, Randomised, Cross-over Study Evaluating Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease & Hyperkalaemia (APPETIZE).
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis
A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

343 Total Publications

AI IN ROBOTIC-ASSISTED PEDIATRIC SURGERY: CURRENT APPLICATIONS AND FUTURE DIRECTIONS.
AI IN ROBOTIC-ASSISTED PEDIATRIC SURGERY: CURRENT APPLICATIONS AND FUTURE DIRECTIONS.
Journal: European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie
Published: October 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Esposito's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 12 Advanced Conditions
View All 82 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile